Clinical decision-support only. Not for direct patient use. Use alongside local policy, senior clinical judgement, and patient-specific context. Proposed tools are placeholders and must not be used for any clinical decision. See the governance page for scope, limitations, and medico-legal framing.
Live Published and usable today
Beta Draft-ready; review feedback welcome
Proposed Placeholder only; no clinical content yet

1. Flagship

1 live

The primary featured tool. Structured haematology interpretation and decision support.

2. General Haematology Interpretation

2 live · 8 proposed

Structured interpretation of full blood count findings, iron and B12 metabolism, and other core general haematology investigations.

Anaemia in Pregnancy Guideline

Live

UK consultant-grade clinical guideline: trimester thresholds, ferritin interpretation, oral and IV iron pathways, postpartum bands, transfusion.

  • Interpretation
  • BSH
  • NICE
  • Prescribing
Open guideline →

ITP in Adults Guideline

Live

Consultant-grade guideline summary for immune thrombocytopenia in adults: diagnosis of exclusion, when to treat vs observe, first-line and second-line.

  • Interpretation
  • BSH
  • NICE
Open guideline →

Cytopenia Decision Engine

Proposed

Step-by-step structured approach to investigating single and multi-lineage cytopenias.

  • Interpretation
  • BSH

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Anaemia Pattern Interpreter

Proposed

Microcytic, normocytic, and macrocytic pattern workup with red-flag prompts.

  • Interpretation
  • BSH
  • NICE

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Iron Studies Interpreter

Proposed

Structured interpretation of ferritin, serum iron, TIBC, and transferrin saturation.

  • Interpretation
  • NICE
  • BSH

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Macrocytosis Workup Tool

Proposed

Structured workup covering B12, folate, thyroid, liver, reticulocytes, MDS flags.

  • Interpretation

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Lymphocytosis Assessment Tool

Proposed

Benign versus malignant lymphocytosis workup, when to send flow cytometry.

  • Interpretation
  • BSH

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Thrombocytosis Assessment Tool

Proposed

Reactive vs clonal thrombocytosis, JAK2/CALR/MPL workup, referral triggers.

  • Interpretation
  • BSH

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Eosinophilia Assessment Tool

Proposed

Reactive vs clonal eosinophilia, parasitic and drug aetiologies, FIP1L1-PDGFRA.

  • Interpretation

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Splenomegaly Initial Assessment Tool

Proposed

Differential for palpable splenomegaly with imaging and workup checklist.

  • Interpretation

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

3. Coagulation and Thrombosis

1 live · 8 proposed

Coagulation screen interpretation, DOAC and warfarin management, and VTE pathway support.

Cancer-Associated Thrombosis

Live

Evidence-based guideline for cancer-associated VTE: diagnosis, anticoagulant choice, duration, Khorana risk stratification.

  • Interpretation
  • MDT
  • BSH
  • NICE
  • Prescribing
Open guideline →

PT/APTT Abnormality Interpreter

Proposed

Structured approach to abnormal PT and APTT, including pre-analytical and drug causes.

  • Interpretation
  • BSH

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Mixing Study Interpreter

Proposed

50:50 mixing study logic, correction vs inhibitor patterns, next-test logic.

  • Interpretation

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

DOAC Bleeding and Reversal Decision Aid

Proposed

DOAC-specific reversal pathway: apixaban, rivaroxaban, edoxaban, dabigatran. Andexanet, idarucizumab, PCC guidance.

  • Emergency
  • Prescribing
  • BSH
  • NICE

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Warfarin Reversal Decision Aid

Proposed

INR-banded reversal: vitamin K, PCC, FFP. Pre-procedure bridging logic.

  • Emergency
  • Prescribing
  • BSH

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

DIC / Consumptive Coagulopathy Assessment

Proposed

ISTH DIC score, obstetric vs sepsis-driven DIC, supportive management.

  • Emergency
  • Interpretation

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

HIT 4Ts Assessment Tool

Proposed

4Ts score with next-step workup and alternative anticoagulant choice.

  • Interpretation
  • BSH

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

VTE Referral and Anticoagulation Checklist

Proposed

First DVT/PE pathway, provoked vs unprovoked, duration and agent selection.

  • Prescribing
  • NICE

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Peri-procedural Anticoagulation Planning

Proposed

Stop/restart timing for warfarin and DOACs around elective procedures, bridging logic.

  • Prescribing
  • BSH

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

4. Emergency Haematology

6 proposed

Time-critical haematology presentations. Every tool in this category will carry an explicit senior-review escalation instruction. Not a substitute for calling the on-call haematology consultant.

Suspected TTP / MAHA Pathway Tool

Proposed

PLASMIC score, blood film request, ADAMTS13, urgent plasma exchange pathway.

  • Emergency
  • MDT
  • BSH

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

HLH Screening Tool

Proposed

HLH-2004 criteria, H-score, triggers for bone marrow and IL-2R testing.

  • Emergency
  • Interpretation

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Neutropenic Sepsis Initial Management

Proposed

Sepsis-6 + empirical antibiotic logic, MASCC risk index, admission vs ambulatory.

  • Emergency
  • Prescribing
  • NICE

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Hyperviscosity / Leucostasis Risk Tool

Proposed

Symptom clustering, WCC / paraprotein thresholds, urgent leukopheresis pathway.

  • Emergency

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Tumour Lysis Syndrome Risk Tool

Proposed

Cairo-Bishop criteria, risk-stratified prophylaxis, rasburicase indications.

  • Emergency
  • Prescribing

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Severe Bleeding Initial Support Tool

Proposed

Massive haemorrhage protocol triggers, tranexamic acid, fibrinogen replacement logic.

  • Emergency
  • Prescribing

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

5. Malignant Haematology

1 live · 9 proposed

Haematological malignancy workup, prognostic stratification, and MDT-ready summaries. Anchored to BSH, NICE TAs, IMWG, ELN, and iwCLL criteria.

CLL Guideline

Live

Unified clinical guideline covering iwCLL criteria, TP53 / IGHV risk stratification, first-line and relapsed/refractory treatment.

  • Interpretation
  • MDT
  • BSH
  • NICE
Open guideline →

Myeloma CRAB / SLiM-CRAB Assessment

Proposed

IMWG 2024 criteria applied to the workup and MDT submission.

  • Interpretation
  • MDT

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Myeloma Imaging and Referral Checklist

Proposed

Whole-body MRI / low-dose CT pathway and bone marrow workup logic.

  • MDT
  • Interpretation

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Lymphoma MDT Summary Generator

Proposed

Structured lymphoma MDT summary template: histology, stage, IPI, treatment intent.

  • MDT

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

DLBCL IPI / CNS-IPI Tool

Proposed

International Prognostic Index and CNS-IPI with treatment-intent guidance.

  • Interpretation
  • MDT

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Follicular Lymphoma FLIPI Tool

Proposed

FLIPI and FLIPI-2 with treatment-versus-observe indications.

  • Interpretation
  • MDT

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Mantle Cell Lymphoma MIPI Tool

Proposed

MIPI and MIPI-b risk stratification, fit vs unfit pathway.

  • Interpretation
  • MDT

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

CML ELTS / Sokal Risk Tool

Proposed

ELTS and Sokal scores with first-line TKI selection pointers.

  • Interpretation
  • MDT
  • BSH

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

MDS IPSS-R / IPSS-M Placeholder

Proposed

Links out to validated IWG-PM calculators until a local tool is in place.

  • Interpretation

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

MPN Thrombosis Risk Tool

Proposed

IPSET-thrombosis and ET/PV risk banding with cytoreductive-therapy indications.

  • Interpretation
  • MDT
  • BSH

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

6. Transfusion Medicine

6 proposed

Transfusion thresholds, massive haemorrhage support, reaction workup, and IV iron prescribing.

Red Cell Transfusion Threshold Tool

Proposed

Hb thresholds per patient group: stable, ACS, intensive care, chronic.

  • Interpretation
  • NICE
  • BSH

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Platelet Transfusion Threshold Tool

Proposed

Prophylactic vs procedural thresholds, bleeding thresholds, ABO-matched logic.

  • Interpretation
  • BSH

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Cryoprecipitate / Fibrinogen Tool

Proposed

Fibrinogen replacement threshold and dose guidance in bleeding contexts.

  • Interpretation
  • BSH

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Massive Haemorrhage Haematology Checklist

Proposed

Haematology side of the MHP: product ratios, TEG/ROTEM triggers, decision points.

  • Emergency
  • Prescribing

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Transfusion Reaction Initial Assessment

Proposed

Acute reaction differential: AHTR, TACO, TRALI, febrile non-haemolytic, allergic.

  • Emergency
  • Interpretation

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

IV Iron Dose and Suitability Tool

Proposed

Ganzoni dosing, product-specific limits, anaphylaxis risk, pregnancy-specific rules.

  • Prescribing
  • NICE

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

7. MDT and Pathway Tools

7 proposed

Tools for referral quality, pre-MDT preparation, and NHS cancer pathway timing. Support for MDT coordinators and clinical teams.

Haematology MDT Summary Generator

Proposed

Structured MDT submission template with copy-to-clipboard output.

  • MDT

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

28-Day Faster Diagnosis Standard Tracker

Proposed

Counts working days from referral to communication of diagnosis; flags breach risk.

  • MDT
  • Audit

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

62-Day Cancer Pathway Risk Tracker

Proposed

2-week-wait to first treatment tracker with amber/red banding.

  • MDT
  • Audit

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Referral Quality Checker

Proposed

Does this referral have the right minimum dataset for haematology workup?

  • MDT

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Should this be referred to haematology?

Proposed

Primary-care facing: common abnormalities and which need specialist review.

  • MDT
  • Interpretation

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Watch-and-Wait Documentation Generator

Proposed

Structured W&W letter for indolent lymphoma and CLL follow-up.

  • MDT

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Pre-MDT Investigation Checklist

Proposed

Per-condition pre-MDT investigation lists: myeloma, lymphoma, MDS, CLL.

  • MDT

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

8. Audit and Governance

6 proposed

Audit builders, incident reflection templates, and governance summary generators for local service evaluation.

Neutropenic Sepsis Audit Builder

Proposed

Audit template against NICE NG51 with scoring grid and action log.

  • Audit
  • NICE

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Transfusion Audit Builder

Proposed

SHOT-aligned audit template for transfusion practice and reaction workup.

  • Audit
  • BSH

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

DOAC Reversal Audit Builder

Proposed

Audit template for DOAC-related bleeding and reversal decisions.

  • Audit
  • Prescribing

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Cancer Pathway Delay Review Tool

Proposed

Structured review template for breached 62-day cancer pathways.

  • Audit
  • MDT

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Diagnostic Concordance Audit Tool

Proposed

Comparison of initial diagnosis vs MDT-confirmed diagnosis with RCPath alignment.

  • Audit

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Incident Reflection / Governance Summary

Proposed

Structured governance-report template for haematology incidents.

  • Audit

Proposed tool. Not yet clinically validated. No clinical decision-making should be based on this placeholder.

Educational use only. All tools listed here are intended for clinical decision support, not direct patient use. Local policies, senior clinical judgement, and current national guidelines take precedence. Proposed tools are placeholders only. None of the tools on this page have been formally ratified by any NHS trust governance committee.